Intestinal and enteral stent market, valued at USD 213 million in 2024, is projected to grow steadily and reach USD 325 million by 2031, registering a CAGR of 6.4% during the forecast period (2025–2032). The market’s expansion is driven by rising demand for minimally invasive gastrointestinal (GI) procedures, increasing prevalence of malignant obstructions, and expanding endoscopic intervention capabilities across healthcare systems worldwide.
Explore Key Insights in the Free Sample https://www.24lifesciences.com/download-sample/5652/intestinal-and-enteral-stent-market
As GI disorders, including colorectal cancer, GI obstructions, strictures, and post-surgical complications, become increasingly common, the role of intestinal and enteral stents continues to grow in modern clinical practice. These devices enable effective, minimally invasive management of obstructive disease conditions, significantly reducing surgical burden and improving patient outcomes.
Market Highlights: Growth, Segmentation & Key Insights
By Type
The intestinal and enteral stent market is segmented into:
- Self-Expanding Metal Stents (SEMS): SEMS dominate the market due to their higher radial strength, durability, and growing preference in malignant obstruction management.
- Plastic Stents: These remain relevant in benign strictures and temporary GI drainage solutions due to their cost-effectiveness and easy repositioning or removal.
Increasing clinical inclination toward SEMS, supported by ongoing innovation in stent design, flexibility, and anti-migration technologies, is expected to create continued demand in the coming years.
By Application
- Malignant Obstructions: Represents the largest application segment, propelled by rising global colorectal cancer incidence and the clinical need for non-surgical palliative solutions.
- Benign Strictures: Adoption is rising for conditions related to inflammatory bowel disease (IBD), diverticulitis, and congenital GI narrowing.
- Post-Surgical Complications: Demand is increasing as stents help reduce hospital stay duration and prevent recurrent surgical intervention.
- Others: Includes specialized interventions such as enteral feeding support and GI bypass procedures.
By End User
- Hospitals: Lead the global market, driven by higher patient intake, advanced endoscopic infrastructure, and a broader pool of interventional specialists.
- Specialty Clinics: Expected to grow steadily due to rising outpatient endoscopy adoption, especially in North America and Europe.
- Ambulatory Surgical Centers (ASCs): Rapidly growing due to cost efficiency, reduced recovery time, and increasing preference for same-day GI interventions.
Explore Key Insights in the Free Sample https://www.24lifesciences.com/download-sample/5652/intestinal-and-enteral-stent-market
Emerging Trends Shaping the Healthcare Market
The integration of advanced technologies continues to reshape the intestinal and enteral stent market. Innovations such as artificial intelligence (AI)-powered imaging, robotic endoscopy, precision-guided stent deployment, and digital health platforms are improving diagnostic accuracy and treatment outcomes. AI-enhanced endoscopic visualization is enabling earlier detection of complex GI lesions, increasing the demand for minimally invasive therapeutic options.
In parallel, sustainability trends in life sciences are influencing the development of more biocompatible, durable, and environmentally safe stent materials. These advancements are expected to accelerate GI device innovation through 2032.
Competitive Landscape: Leading Intestinal and Enteral Stent Companies
The market features a strong competitive landscape with several major global players focusing on innovation, regulatory approvals, and strategic expansion. Key companies profiled include:
- Boston Scientific Corporation (USA)
- Abbott Laboratories (USA)
- Medtronic plc (Ireland)
- Olympus Corporation (Japan)
- Cook Medical (USA)
- CONMED Corporation (USA)
- B. Braun Melsungen AG (Germany)
- ELLA-CS s.r.o. (Czech Republic)
These companies continue to invest in R&D, product portfolio expansion, and clinical collaborations to strengthen their global footprint. Strategies include next-generation SEMS design enhancements, metallic alloy innovation, acquisition of smaller GI device firms, and global distribution partnerships.
Gain Full Market Insights – Access the Complete Report https://www.24lifesciences.com/intestinal-and-enteral-stent-market-5652
Strategic Outlook
With a projected 6.4% CAGR through 2032, the intestinal and enteral stent market is set for consistent expansion. Increasing clinical need for minimally invasive GI obstruction management, combined with advancement in material sciences and imaging technology, is expected to reshape product development landscapes. Growing adoption across hospitals and outpatient centers will further contribute to long-term market growth.
Explore our related reports
About 24lifesciences
Founded in 2017, 24LifeScience has emerged as a trusted research and analytics partner for organizations operating within the global life sciences and chemical industries. Our core mission is to provide intelligent, future-ready insights that help clients stay ahead in an increasingly complex and innovation-driven market
International: +1(332) 2424 294 | Asia: +91 9425150513 (Asia)
Website: www.24lifesciences.com
Follow us on LinkedIn: www.linkedin.com/company/lifesciences24
- Single-Domain Heavy Chain Antibody Market - 2026-01-23
- Qianlie Antong Capsules Market - 2026-01-23
- Veterinary Amitraz Solution Market - 2026-01-23